OptiBiotix (OPTI) on Wednesday appointed Mikkel Hvid-Hansen as its new European Sales Leader for ProBiotix Health, its subsidiary developing probiotics to reduce cardiovascular risk.
Mr. Hansen is to join the AIM-listed firm from Cell Biotech Int., a Korean listed probiotic company that sells bulk ingredients and finished products internationally.
He was previously an International Sales Manager for several probiotic OTC drugs at Bifodan, a Danish probiotic company, and before served at Lallemand, the world’s third largest probiotic company.
OptiBiotix said Mikkel brought extensive experience commercialising probiotics products, a wide network of industry contacts, and a strong track record of rapidly growing sales.
Steve Prescott, CEO of ProBiotix Health Ltd., said: "Mikkel's experience and track record of launching new products and growing sales within Europe brings over 20 years of commercial and probiotic industry expertise to OptiBiotix's wholly owned probiotic subsidiary, ProBiotix Health Ltd.”
Mr. Prescott continued: “His network of contacts provides access to key customers which we hope will continue to drive revenue growth of LPLDL® in supplement, food and pharmaceutical products around the world.”
He said: “We are delighted that Mikkel has joined ProBiotix Health at such an exciting stage of its development transforming the company from R&D to commercial sales focused."
OptiBiotix said Mikkel will be based in Denmark to support existing sales in Europe and extend the market opportunities for LPLDL® within the European probiotic supplement, food, and dairy markets.
Since the firm launched its CholBiome® products containing LPLDL® in May 2017, it has signed over 23 agreements with products commercialised in 23 countries, recently being designated Generally Recognized As Safe (GRAS) by an independent US panel earlier this year.
Follow News & Updates from OptiBiotix Health here: